Sygnature Discovery expands DMPK with XenoGesis acquitision

Sygnature has significantly expanded its DMPK capabilities and expertise with the acquisition of XenoGesis, the UK’s largest independent laboratory-based CRO specialising in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation.

This latest acquisition (in recent years they have also broadened their integrated drug discovery offering through the addition of in vivo pharmacology CROs RenaSci and Alderley Oncology) serves to meet both their increasing demand for DMPK services and boost their reach into the pre-clinical space.

XenoGesis' novel consultative approach has achieved a strong track record of success since its inception in 2011 through its focus on high-quality science and a forward-thinking methodology that always has clinical considerations in mind from the outset of a drug discovery project, resulting in the early prediction of PK and likely human dosage, and enabling more successful candidate molecules.

This acquisition effectively doubles the size of Sygnature's DMPK department (established in 2015), broadening their discovery and development expertise, while complementing their existing service offering.

Dr Simon Hirst, CEO and Founder at Sygnature, commented:

“Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process, and we recognise the central role that DMPK plays in that journey.

“Sygnature is not growing for the sake of growing. We believe that truly integrated drug discovery is the best possible way forward in bringing novel efficacious drug candidates to man; that having teams working together across every discipline involved in a research project, sharing ideas and resolving challenges, will produce the sparks of innovation and high-quality science needed to enable success.

“We have always had tremendous respect for the work that XenoGesis does, and have a strong history of collaboration with them over the years. We are thrilled at this opportunity to build on the capabilities of both companies and enrich our service-offering going forward together.”